Prognosis method for blood disorders

Patent metadata

Field	Value
Publication number	US-12517043-B2
Application number	US-202117927480-A
Country	US
Kind code	B2
Filing date	May 24, 2021
Priority date	May 25, 2020
Publication date	Jan 6, 2026
Grant date	Jan 6, 2026

Abstract

A method for determining the risk of developing a blood disorder, which includes the steps of: exposing a biological sample from an individual to radiation to obtain a spectrum characteristic of the sample, the spectrum being processed in order to obtain a spectral signature; comparing the spectral signature obtained with one or more reference spectral signatures; and concluding, if the spectral signature of the individual is significantly different from control spectral signatures, that the individual is likely to develop a blood disorder, and, if not, that the individual is not likely to develop a blood disorder.

First claim

The invention claimed is:

1 . A method for determining, in vitro, the risk for an individual of developing a blood disorder, from a biological sample of said individual, said method comprising the following steps:
exposing said biological sample to mid-infrared radiation (MIR) of wavelength varying from 4000 cm −1 to 400 cm −1 to obtain a spectrum characteristic of said sample; processing said spectrum using Fourier transform followed by generating a second derivative of the Fourier transform in order to obtain a spectral signature made up of absorbance peaks characteristic due to their position, or wave number, and their intensity, or absorbance, of the type and the relative concentrations of the various molecules present in said sample; comparing said spectral signature obtained in the previous step with one or more reference spectral signatures, said one or more reference spectral signatures being obtained from a reference population of individuals and being processed using Fourier transform followed by generating a second derivative; and concluding that: (i) if the intensities of a first group of peaks of the spectral signature of said individual is significantly different from the intensities of these same peaks obtained in the reference spectral signature(s), that the individual is likely to develop a blood disorder, the first group of peaks corresponding to the wave numbers of the following first group: 1330 cm −1 , 1445 cm −1 , 1478 cm −1 , 1493 cm −1 , 1505 cm −1 , 1507 cm −1 , 1520 cm −1 , 1526 cm −1 , 1544 cm −1 , 1571 cm −1 , 1602 cm −1 , 1668 cm −1 , 1674 cm −1 , 1676 cm −1 , 1697 cm −1 , and 2852 cm −1 , and (ii) if not, that the individual is not likely to develop a blood disorder, and tracking the individual if the individual is likely to develop a blood disorder.

2 . The method according to claim 1 , wherein, when the individual is likely to develop a blood disorder, it is furthermore concluded that:
(i) if the intensities of a second group of peaks of the spectral signature of said individual is significantly different from the intensities of these same peaks obtained in the reference spectral signature(s), that the individual is likely to develop leukemia, the second group of peaks corresponding to the wave numbers of the following first group: 3316 cm −1 , 3283 cm −1 , 3281 cm −1 , 3256 cm −1 , 3118 cm −1 , 3116 cm −1 , 1345 cm −1 , 1343 cm −1 , 1340 cm −1 and 1338 cm −1 , and (ii) if not, that the individual is likely to develop a myelodysplastic syndrome.

3 . The method according to claim 2 , wherein, when the individual is likely to develop a myelodysplastic syndrome, it is furthermore concluded that:
(i) if the intensities of a third group of peaks of the spectral signature of said individual is significantly different from the intensities of these same peaks obtained in the reference spectral signature(s), that the individual is likely to develop a low-risk myelodysplastic syndrome, the third group of peaks corresponding to the wave numbers of the following first group: 3060 cm −1 , 3062 cm −1 , 3396 cm −1 , 3384 cm −1 and 3052 cm −1 , and (ii) if not, that the individual is likely to develop a high-risk myelodysplastic syndrome.

4 . The method according to claim 2 , wherein, when the individual is likely to develop leukemia, it is concluded that:
(i) if the intensities of a fourth group of peaks of the spectral signature of said individual is significantly different from the intensities of these same peaks obtained in the reference spectral signature(s), that the individual is likely to develop a secondary leukemia, the fourth group of peaks corresponding to the wave numbers of the following first group: 3270 cm −1 , 3268 cm −1 , 3266 cm −1 , 3264 cm −1 , 3192 cm −1 , 3190 cm −1 , 2850 cm −1 , 2840 cm −1 , 1707 cm −1 , 1705 cm −1 , 1664 cm −1 , 1662 cm −1 , 1633 cm −1 , 1631 cm −1 , 1493 cm −1 , 1491 cm −1 , 1489 cm −1 , 1458 cm −1 , 1456 cm −1 and 1256 cm −1 , and (ii) if not, that the individual will be likely to develop to develop de novo leukemia.

5 . The method according to claim 1 , wherein said biological sample is a blood plasma sample.

6 . A computer program product comprising portions, means or program code instructions for executing the steps of the method according to claim 1 when said program is executed on a computer.

Assignees

• Centre Nat Rech Scient
• Centre Hospitalier Regional Univ De Tours
• Univ Tours

Inventors

• Herault Olivier
• Sire Olivier

Classifications

• G01N2021/451

  for determining the optical absorption · CPC title

• G01N2201/129

  Using chemometrical methods · CPC title

• G01N2021/3595

  using FTIR · CPC title

• G01N21/552 Primary

  Attenuated total reflection · CPC title

• G01N21/3577 Primary

  for analysing liquids, e.g. polluted water · CPC title